Chugai, DSP end WT1 cancer vaccine tie-up
This article was originally published in Scrip
Executive Summary
Dainippon Sumitomo Pharma (DSP) and Roche's Japanese subsidiary Chugai have ended an agreement for the joint development and commercialization of two peptide therapeutic vaccines for cancer, with DSP to take on future sole responsibility for these.